{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T03:01:42Z","timestamp":1789786902245,"version":"4.0.1"},"reference-count":57,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2026,11,1]]},"abstract":"<jats:p>The purpose is to review the role of the nitric oxide (NO)\u2013soluble guanylate cyclase (sGC)\u2013cyclic guanosine monophosphate (cGMP) signaling pathway in glaucoma, focusing on trabecular meshwork (TM) function, aqueous humor outflow, intraocular pressure (IOP), and ocular fibrosis. A structured narrative review of PubMed\/MEDLINE, Embase, and Web of Science identified peer-reviewed studies published from January 2000 to March 2026 using terms including \u201csoluble guanylate cyclase,\u201d \u201csGC stimulator,\u201d \u201csGC activator,\u201d \u201ccGMP,\u201d \u201cnitric oxide,\u201d \u201cglaucoma,\u201d \u201ctrabecular meshwork,\u201d \u201caqueous humor outflow,\u201d and \u201cocular hypertension.\u201d Experimental studies involving TM cells, Schlemm\u2019s canal endothelial cells, ocular fibroblasts, anterior segment perfusion systems, animal models, and human clinical investigations were qualitatively reviewed. Evidence supports an important role for NO\u2013sGC\u2013cGMP signaling in regulating conventional aqueous humor outflow. sGC activation increases intracellular cGMP and promotes protein kinase G\u2013mediated modulation of cytoskeletal organization and RhoA\/Rho kinase signaling, reducing TM contractility and increasing outflow facility. cGMP signaling may also regulate extracellular matrix remodeling and transforming growth factor-\u03b2\u2013associated fibrotic responses in ocular tissues. Preclinical studies demonstrate enhanced outflow facility and reduced IOP after pharmacologic pathway activation. Clinical evidence is strongest for NO-donating therapies such as latanoprostene bunod, whereas direct evidence for selective sGC stimulators and activators remains limited. The NO\u2013sGC\u2013cGMP pathway is a promising therapeutic target in glaucoma, particularly for trabecular outflow regulation and IOP control. Despite consistent mechanistic preclinical evidence, translational challenges remain, including drug delivery, tissue-specific pharmacodynamics, and limited clinical evaluation of direct sGC modulators. Further studies are needed to define the therapeutic role of selective sGC-targeted strategies in glaucoma management.<\/jats:p>","DOI":"10.1177\/10807683261459859","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:12:02Z","timestamp":1781244722000},"page":"545-555","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Soluble Guanylate Cyclase Modulators in Glaucoma and Ocular Fibrosis: Mechanisms, Translational Evidence, and Therapeutic Challenges"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4369-9763","authenticated-orcid":false,"given":"M.S.A.","family":"Mohamed","sequence":"first","affiliation":[{"name":"MSAM Clinic, Bredstedt, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100922"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2025.12.013"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2025.07.001"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100897"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom12111671"},{"key":"e_1_3_7_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.5c00424"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0183-2023"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18958"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232315325"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2022.107023"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118762"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2018_197"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2020-317262"},{"key":"e_1_3_7_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2025.1554777"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.05.015"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2021.09.001"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-16534-z"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.1007768"},{"key":"e_1_3_7_20_1","volume-title":"StatPearls","author":"Iheanacho F","year":"2026","unstructured":"19.Iheanacho F, , Rahimi N. Biochemistry, cyclic GMP. In: StatPearls. StatPearls Publishing: Treasure Island, FL; 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542234\/"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-019-01779-z"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2022.1076799"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13738"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041001"},{"key":"e_1_3_7_25_1","first-page":"2145","article-title":"Role of nitric oxide in trabecular meshwork physiology","volume":"56","author":"Chang JY","year":"2015","unstructured":"24.Chang JY, , Stamer WD, , Bertrand J, et al. Role of nitric oxide in trabecular meshwork physiology. Invest Ophthalmol Vis Sci 2015;56:2145\u20132155.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_7_26_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2750"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13040360"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12202"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042145"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00997-9"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2019.0057"},{"key":"e_1_3_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.11.019"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2022.948397"},{"key":"e_1_3_7_34_1","first-page":"116","article-title":"Discovery and preclinical development of netarsudil, a novel rho kinase inhibitor for the treatment of glaucoma","volume":"166","author":"Lin CW","year":"2018","unstructured":"33.Lin CW, , Sherman B, , Moore LA, et al. Discovery and preclinical development of netarsudil, a novel rho kinase inhibitor for the treatment of glaucoma. Exp Eye Res 2018;166:116\u2013124.","journal-title":"Exp Eye Res"},{"issue":"6","key":"e_1_3_7_35_1","first-page":"2932","article-title":"Modulation of extracellular matrix turnover in the trabecular meshwork","volume":"50","author":"Fuchshofer R","year":"2009","unstructured":"34.Fuchshofer R, , Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Invest Ophthalmol Vis Sci 2009;50(6):2932\u20132940.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.12.012"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2014.00038"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26237306"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-24943"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-23772"},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.62.3.17"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/IJG.0000000000000831"},{"issue":"02","key":"e_1_3_7_43_1","first-page":"80","article-title":"Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure","volume":"09","author":"Weinreb RN","year":"2016","unstructured":"42.Weinreb RN, , Realini T, , Varma R. Latanoprostene bunod, a dual-acting nitric oxide donating prostaglandin analog for lowering of intraocular pressure. US Ophthalmic Rev 2016;09(02):80\u201387.","journal-title":"US Ophthalmic Rev"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.019"},{"key":"e_1_3_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2016.05.012"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11154325"},{"key":"e_1_3_7_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0385-7"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00307-0"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-biochem-050410-100030"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2038"},{"key":"e_1_3_7_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209655"},{"key":"e_1_3_7_52_1","first-page":"51","article-title":"Targeting the heme-oxidized nitric oxide receptor","volume":"164","author":"Stasch JP","year":"2011","unstructured":"51.Stasch JP, , Schmidt PM, , Nedvetsky PI, et al. Targeting the heme-oxidized nitric oxide receptor. Br J Pharmacol 2011;164:51\u201362.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_7_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-68964-5_13"},{"key":"e_1_3_7_54_1","first-page":"3623","article-title":"PDE5 expression in ocular tissues","volume":"46","author":"Lin CS","year":"2005","unstructured":"53.Lin CS, , Chow S, , Lau A, et al. PDE5 expression in ocular tissues. Invest Ophthalmol Vis Sci 2005;46:3623\u20133629.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_7_55_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00030.2010"},{"key":"e_1_3_7_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2008.11.033"},{"key":"e_1_3_7_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.925457"},{"key":"e_1_3_7_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-34243-5"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261459859","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10807683261459859","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10807683261459859","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:16:12Z","timestamp":1789784172000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10807683261459859"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,11,1]]}},"alternative-id":["10.1177\/10807683261459859"],"URL":"https:\/\/doi.org\/10.1177\/10807683261459859","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}